Social phobia is a chronic, debilitating, prevalent condition for which few effective treatments exist. The only medication established to be effective in a large double blind trial is the monoamine oxidase inhibitor phenelzine. Recent studies with phenelzine suggest that approximately 65% of social phobic patients improve significantly with treatment, but a high incidence of impaired function due to adverse effects now this medication intolerable for marry patients. Moclobemide is a type A specific reversible MAOI which has been marketed as an ant in Europe but not in the U.S. In therapeutic trials with more than 2000 patients, it has been shown to be effective for depression with less adverse effects than other MAOIs or tricyclics. One double blind controlled study of moclobemide in patients with social phobia suggests that moclobemide is equally effective as phenelzine and is far better tolerated. Tyramine challenge studies indicate that there is far less risk of hypertensive crisis with moclobemide than with marketed MAOIs. Nevertheless, trials of moclobemide in social phobia have not attracted financial sponsorship from the American manufacturer. In this proposal, 90 social phobic patients will be entered to be treated on an outpatient double blind basis with either moclobemide or placebo for 8 weeks, and responders will continue for an additional 8 weeks. Outcome will be rated on a double-blind basis by an independent evaluator who will also be blind to any adverse effects. Adverse effects will be rated by the treating psychiatrist. When completed, the study should provide an objective t of the efficacy and safety of moclobemide in social phobia.

National Institute of Health (NIH)
National Institute of Mental Health (NIMH)
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
Application #
Study Section
Treatment Development and Assessment Research Review Committee (TDA)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York State Psychiatric Institute
New York
United States
Zip Code
Zaider, T I; Heimberg, R G; Fresco, D M et al. (2003) Evaluation of the clinical global impression scale among individuals with social anxiety disorder. Psychol Med 33:611-22
Eng, W; Heimberg, R G; Coles, M E et al. (2000) An empirical approach to subtype identification in individuals with social phobia. Psychol Med 30:1345-57
Safren, S A; Heimberg, R G; Horner, K J et al. (1999) Factor structure of social fears: The Liebowitz Social Anxiety Scale. J Anxiety Disord 13:253-70
Heimberg, R G; Horner, K J; Juster, H R et al. (1999) Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med 29:199-212
Schneier, F R; Goetz, D; Campeas, R et al. (1998) Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 172:70-7
Liebowitz, M R; Schneier, F; Gitow, A et al. (1993) Reversible monoamine oxidase-A inhibitors in social phobia. Clin Neuropharmacol 16 Suppl 2:S83-8